Share

September 09, 2014; 83 (11) Global Perspectives

Atlas of Multiple Sclerosis 2013: A growing global problem with widespread inequity

Paul Browne, Dhia Chandraratna, Ceri Angood, Helen Tremlett, Chris Baker, Bruce V. Taylor, Alan J. Thompson
First published September 8, 2014, DOI: https://doi.org/10.1212/WNL.0000000000000768
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
12336

Share

Article Information

vol. 83 no. 11 1022-1024
DOI: 
https://doi.org/10.1212/WNL.0000000000000768
PubMed: 
25200713
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Print ISSN: 
0028-3878
Online ISSN: 
1526-632X
History: 
  • First Published September 8, 2014.
Copyright & Usage: 
© 2014 American Academy of Neurology

Author Disclosures

    1. Paul Browne, PhD,
    2. Dhia Chandraratna, PhD,
    3. Ceri Angood, MPH,
    4. Helen Tremlett, PhD,
    5. Chris Baker, MPH,
    6. Bruce V. Taylor, MD and
    7. Alan J. Thompson, MD, FRCP
  1. Paul Browne, PhD,
    2. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. (1) Biogen Idec, (2)Genzyme, (3) Novartis, (4) Merck Serono, (5) Synthon, (6) Teva

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. (1) Vanneau Trust

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Dhia Chandraratna, PhD,
    3. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. Multiple Sclerosis International Federation, Head of Research

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  3. Ceri Angood, MPH,
    4. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  4. Helen Tremlett, PhD,
    5. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. Dr Helen Tremlett is funded by the Multiple Sclerosis Society of Canada (Don Paty Career Development Award), Michael Smith Foundation for Health Research and is the Canada Research Chair for Neuroepidemiology and Multiple Sclerosis. She has received: research support from the US National Multiple Sclerosis Society, CIHR, and UK MS Trust; speaker honoraria and/or travel expenses to attend conferences from the Consortium of MS Centres, US National MS Society, the University of British Columbia Multiple Sclerosis Research Program, Bayer Pharmaceutical (speaker, 2010, honoraria declined), Teva Pharmaceuticals (speaker 2011), ECTRIMS (2011, 2012, 2013), UK MS Trust (2011), the Chesapeake Health Education Program, US Veterans Affairs (2012, honorarium declined), Novartis (2012) and the Consortium of MS Centers (2013). Unless otherwise stated, all speaker honoraria are either donated to an MS charity or to an unrestricted grant for use by her research group.

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. Canadian Institutes of Health Research [#190898 (PI) and #MOP-82738 (PI)]; the US National Multiple Sclerosis Society (Operating grants: 2006-09 and 2009-12), the Multiple Sclerosis Society of Canada (Don Paty Career Development Award, 2004-present), and a Michael Smith Foundation for Health Research Scholar Award (2006- present); Canada Research Chair in Neuroepidemiology and Multiple Sclerosis

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  5. Chris Baker, MPH,
    6. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. (1) London School of Hygiene and Tropical Medicine, Research Fellow, 0.3 years

    Consultancies:

    1. (1) Multiple Sclerosis International Federation (2) Department of Chemistry, University of Washington

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. (1) University of Washington, Seattle, Washington, USA

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  6. Bruce V. Taylor, MD and
    7. Scientific Advisory Boards:

    1. Biogen Idec Tecfidera advisory board Australia

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. Funding to travel to World Congress of MS Montreal September 2008 from Bayer Schering Pharma Pty Ltd Funding for travel and accommodation from MS Society of Western Australia to speak at their 2008 scientific. meeting. Funding from Bayer Schering Pharma to present a series of lectures in South East Asia March 2008 Invited Guest speaker at Asia pacific MS forum funded by Bayer Schering Pharma Pty Ltd Invited guest speaker INDAPS meeting Melbourne Nov 2008 funded by CSL Pty Ltd Austrlaia. Funding to travel to AAN meeting Seattle 2009 from Bayer Schering Pharma. Funding to travel to ECTRIMS Gothenberg 2010 from Bayer Schering Pharma. Funding to travel to ECTRIMS meeting Lyon France 2012 fromBayer Schering. Funding to travel to AAN San Diego 2013from Novartis. Funding to Travel to ECTRIMS 2013 from Novartis

    Editorial Boards:

    1. International MS Journal Editorial Advisary Board 2009 - 2012 Journla of Neurology Neurosrugery and Psychiatry Editorial Board From Jan 2013

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. Honoraria received from MS society of Western Australia for speaking at the 2008 Scientific meeting

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NHMRC australia project grant support.2008-9.490020, 2009 544922 2010 2012 1047180 HRC New Zealand project grant support.2007-8 05/524 National MS Society of USA project grant support Australian research Council and MS Research Australia 2007-9 LP0776744 National MS society of US project grant funding

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. Ms society of Tasmania research fellowship support 2007 - 2009

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  7. Alan J. Thompson, MD, FRCP
    8. Scientific Advisory Boards:

    1. (1) Eisai Ltd, Chair of the Advisory Committee (Clinical Neuroscience)2010-March 2013, honorarium to UCL; (2) Chair of the Eisai-UCL Joint Steering Committee for Neuroscience April 2013 to date, honorarium to UCL (3) Imanova, Board member,2012-2014,no compensation; (4) Genzyme, member European Advisory Board (Teriflunomide, Alemtuzumab), June 2013, honorarium and support for travel; (5) Biogen Idec, 14 March 2014, honorarium and support for travel; (6) medDay, 6 May 2014, honorarium and support for travel.

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. (1) Serono Symposia International Foundation (EXCEMED), Invited lectures,honoraria and support for travel; 2) Novartis, Invited lecturer, honorarium and support for travel; (3) Teva, Invited lecturer, honorarium; (4) Remedica, invited lecturer, honorarium and support for travel.

    Editorial Boards:

    1. (1) Multiple Sclerosis Journal,Editor-in-Chief, 2006 to date,honorarium (2) Lancet Neurology,Editorial Advisory Board, 2007 to date, free subscription

    Patents:

    1. NONE

    Publishing Royalties:

    1. Multiple Sclerosis, Cambridge University Press, 2011

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. (1) Development Foundation, Brain Appeal, National Hospital for Neurology and Neurosurgery, Queen Square, London, trustee, no remuneration. (2) National Institute for Health Research, Senior Investigator, honorarium. (3) Multiple Sclerosis International Federation (MSIF), Board member and Chair of the International Medical and Scientific Board, no remuneration, support for travel. (4) International Progressive MS Alliance, chair Scientific Advisory Committee, no remuneration, support for travel. (5) National Multiple Sclerosis Society, member, Research Programs Advisory Committee,member, no remuneration, support for travel. (6) The Worshipful Company of Pewterers, trustee, no remuneration.

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. (1) Eisai Inc. to support PhD students at Leonard Wolfson Experimental Neuroscience Centre,Queen Square, London 2012-2017.

    Research Support, Government Entities:

    1. (1) NIHR Comprehensive Biomedical Research Centre, co- applicant, New Initiative ref 20, 1/1/2009-31/12/2012; (2) NIHR, Senior Investigator, 2008-2016

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. (1) Medical Research Council, grant ref MC_PC_12024, 2012- 2014; (2) The Wolfson Foundation, grant ref 18575, 2012- 2017; (3) Wellcome Trust, grant ref 097815/Z/11/Z, 2012- 2013;grant ref 099557/Z/12/A; (4) Multiple Sclerosis Society of GB, award 984,2013-2018; SRH Holding, project 2012-910001, 2012-2014

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From the Multiple Sclerosis International Federation (P.B., D.C., C.A.), London, UK; University of British Columbia (H.T.), Vancouver, Canada; Department of Non-Communicable Disease Epidemiology (C.B.), London School of Hygiene and Tropical Medicine, London, UK; Menzies Research Institute Tasmania (B.V.T.), University of Tasmania, Hobart, Australia; and Faculty of Brain Sciences (A.J.T.), University College London and National Hospital for Neurology and Neurosurgery, Queen Square, London, UK.
  1. Correspondence to Dr. Thompson: alan.thompson{at}ucl.ac.uk
View Full Text

Article usage

Article usage: September 2014 to December 2022

AbstractFullPdfSource
Sep 20141125206294Highwire
Oct 2014827881Highwire
Nov 201479191118Highwire
Dec 2014287454Highwire
Jan 2015385045Highwire
Feb 2015525754Highwire
Mar 2015944662Highwire
Mar 201504121pmc
Apr 2015653630Highwire
Apr 201505127pmc
May 2015684738Highwire
May 201507930pmc
Jun 2015502924Highwire
Jun 201507123pmc
Jul 2015632950Highwire
Jul 201507721pmc
Aug 2015782437Highwire
Aug 201507223pmc
Sep 2015572330Highwire
Sep 201507320pmc
Oct 2015402246Highwire
Oct 2015012142pmc
Nov 2015692235Highwire
Nov 2015011828pmc
Dec 2015412622Highwire
Dec 2015010122pmc
Jan 2016413920Highwire
Jan 2016010530pmc
Feb 2016532931Highwire
Feb 2016012338pmc
Mar 2016843848Highwire
Mar 2016013443pmc
Apr 2016822136Highwire
Apr 2016015550pmc
May 2016712347Highwire
May 2016014724pmc
Jun 2016422734Highwire
Jun 2016012823pmc
Jul 2016321918Highwire
Jul 201609835pmc
Aug 2016421632Highwire
Aug 201609930pmc
Sep 2016621546Highwire
Sep 2016015333pmc
Oct 20167127122Highwire
Oct 2016018333pmc
Nov 20167119146Highwire
Nov 2016018936pmc
Dec 20164222119Highwire
Dec 2016012324pmc
Jan 20177037113Highwire
Jan 2017019044pmc
Feb 20177420131Highwire
Feb 2017022355pmc
Mar 20176926119Highwire
Mar 2017026950pmc
Apr 20178928163Highwire
Apr 201750186223pmc
May 20177227128Highwire
May 201772287327pmc
Jun 20175636120Highwire
Jun 201750170194pmc
Jul 2017722097Highwire
Jul 201739225346pmc
Aug 2017821771Highwire
Aug 201757272328pmc
Sep 2017632392Highwire
Sep 201762263323pmc
Oct 20178733119Highwire
Oct 201781434532pmc
Nov 20176537106Highwire
Nov 201779361455pmc
Dec 2017506636Highwire
Jan 20184712243Highwire
Feb 20188013557Highwire
Mar 20188512456Highwire
Apr 20188317168Highwire
Apr 201865446566pmc
May 20186811473Highwire
Jun 20185612756Highwire
Jun 201855332408pmc
Jul 2018487828Highwire
Aug 20187212261Highwire
Aug 201868361451pmc
Sep 20187311163Highwire
Oct 20187919194Highwire
Nov 201892159110Highwire
Dec 201842139119Highwire
Jan 20195914063Highwire
Feb 201918215568Highwire
Mar 2019418157103Highwire
Apr 20198413364Highwire
May 201910017758Highwire
Jun 20195312471Highwire
Jul 20193911465Highwire
Aug 20194215275Highwire
Sep 2019589775Highwire
Oct 20195313069Highwire
Nov 20196416564Highwire
Dec 2019498139Highwire
Jan 2020499254Highwire
Feb 20205612155Highwire
Mar 20205015972Highwire
Apr 20204914399Highwire
May 20203912969Highwire
Jun 2020399256Highwire
Jul 2020417255Highwire
Aug 20203410742Highwire
Sep 202042153290Highwire
Oct 20203713564Highwire
Nov 20205812155Highwire
Dec 20204613770Highwire
Jan 20213311479Highwire
Feb 202168131103Highwire
Mar 20215511180Highwire
Apr 20216435972Highwire
May 20215731478Highwire
Jun 20214026364Highwire
Jul 20212325365Highwire
Aug 20213821072Highwire
Sep 20214225775Highwire
Oct 20213932087Highwire
Nov 20218030092Highwire
Dec 20213327870Highwire
Jan 20224230172Highwire
Feb 20224034288Highwire
Mar 20225137783Highwire
Apr 20227363492Highwire
May 20225040969Highwire
Jun 20225334761Highwire
Jul 20223531549Highwire
Aug 20224685453Highwire
Sep 20222675944Highwire
Oct 20225582460Highwire
Nov 20225396664Highwire
Dec 20224363669Highwire

Cited By...

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

  • No related articles found.

Topics Discussed

Alert Me